Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Dow
Moodys
McKesson
McKinsey

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR PARAPLATIN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


505(b)(2) Clinical Trials for Paraplatin

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00186888 ↗ Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Active, not recruiting National Cancer Institute (NCI) Phase 3 2005-04-07 Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain. When only one eye is affected, this is known as unilateral retinoblastoma and when both eyes are affected, it is called bilateral retinoblastoma. Treatment for retinoblastoma is individualized for each patient and is based on the form and the stage of the disease (inside the eye or has moved outside). The main goal is always to cure the cancer, and save the life of the child. Treatments are also designed with the hope of saving the vision, while completely destroying the tumor. Therapies may involve surgery, chemotherapy, radiation, and other treatments called focal treatments. Focal treatments may be laser therapy, freezing, or heat treatments meant to shrink and kill the tumor. In this study, researchers want to investigate how different participants respond to different therapies that are individualized specifically for them. Participants will be divided into three main groups, depending on whether the disease is unilateral or bilateral, and the stage of the disease. One of the main objectives of the study is to investigate how advanced tumors in children with bilateral disease respond to a new combination of chemotherapy with topotecan and vincristine, with G-CSF support. In order to improve results, some children with very advanced disease may receive carboplatin chemotherapy given around the eye at the same time that they receive topotecan by vein. Also, because children with retinoblastoma are diagnosed so early in life and the vision may be significantly impaired, this study will investigate how children develop and how the brain adjusts and compensates for the visual deficits. Finally, this study also investigates the biology of retinoblastoma, in order to understand better how this cancer develops.
New Combination NCT00186888 ↗ Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Active, not recruiting St. Jude Children's Research Hospital Phase 3 2005-04-07 Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain. When only one eye is affected, this is known as unilateral retinoblastoma and when both eyes are affected, it is called bilateral retinoblastoma. Treatment for retinoblastoma is individualized for each patient and is based on the form and the stage of the disease (inside the eye or has moved outside). The main goal is always to cure the cancer, and save the life of the child. Treatments are also designed with the hope of saving the vision, while completely destroying the tumor. Therapies may involve surgery, chemotherapy, radiation, and other treatments called focal treatments. Focal treatments may be laser therapy, freezing, or heat treatments meant to shrink and kill the tumor. In this study, researchers want to investigate how different participants respond to different therapies that are individualized specifically for them. Participants will be divided into three main groups, depending on whether the disease is unilateral or bilateral, and the stage of the disease. One of the main objectives of the study is to investigate how advanced tumors in children with bilateral disease respond to a new combination of chemotherapy with topotecan and vincristine, with G-CSF support. In order to improve results, some children with very advanced disease may receive carboplatin chemotherapy given around the eye at the same time that they receive topotecan by vein. Also, because children with retinoblastoma are diagnosed so early in life and the vision may be significantly impaired, this study will investigate how children develop and how the brain adjusts and compensates for the visual deficits. Finally, this study also investigates the biology of retinoblastoma, in order to understand better how this cancer develops.
New Combination NCT05156970 ↗ Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC Recruiting Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Phase 2 2021-06-24 This study is the first clinical study of first-line treatment of head and neck squamous cell carcinoma with drugs targeting VEGF signaling pathway combined with PD-1 inhibitors in China, which explores the new combination therapies urgently needed in clinical practice and lays a foundation for subsequent studies, with important scientific research significance and clinical value.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Paraplatin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002852 ↗ Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 3 1996-10-01 Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have stage I non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether surgery is more effective with or without chemotherapy for non-small cell lung cancer.
NCT00002944 ↗ Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed National Cancer Institute (NCI) Phase 3 1997-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work in treating children with low-grade astrocytomas or other residual tumors of the brain.
NCT00002944 ↗ Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed Children's Oncology Group Phase 3 1997-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work in treating children with low-grade astrocytomas or other residual tumors of the brain.
NCT00003093 ↗ Combination Chemotherapy in Treating Children With Neuroblastoma Completed National Cancer Institute (NCI) Phase 3 1988-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.
NCT00003093 ↗ Combination Chemotherapy in Treating Children With Neuroblastoma Completed Children's Oncology Group Phase 3 1988-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.
NCT00003141 ↗ Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Completed National Cancer Institute (NCI) Phase 1 1998-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctors to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating infants with malignant brain or spinal cord tumors.
NCT00003141 ↗ Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Completed Children's Oncology Group Phase 1 1998-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctors to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating infants with malignant brain or spinal cord tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Paraplatin

Condition Name

Condition Name for Paraplatin
Intervention Trials
Lung Cancer 36
Ovarian Cancer 30
Non-Small Cell Lung Cancer 28
Stage IIIB Non-small Cell Lung Cancer 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Paraplatin
Intervention Trials
Lung Neoplasms 166
Carcinoma 148
Carcinoma, Non-Small-Cell Lung 144
Ovarian Neoplasms 80
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Paraplatin

Trials by Country

Trials by Country for Paraplatin
Location Trials
Australia 92
Japan 90
Spain 61
Argentina 9
Czech Republic 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Paraplatin
Location Trials
Texas 203
California 192
Ohio 179
New York 166
Pennsylvania 162
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Paraplatin

Clinical Trial Phase

Clinical Trial Phase for Paraplatin
Clinical Trial Phase Trials
Phase 4 1
Phase 3 81
Phase 2/Phase 3 11
[disabled in preview] 500
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Paraplatin
Clinical Trial Phase Trials
Completed 241
Recruiting 122
Active, not recruiting 104
[disabled in preview] 127
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Paraplatin

Sponsor Name

Sponsor Name for Paraplatin
Sponsor Trials
National Cancer Institute (NCI) 286
M.D. Anderson Cancer Center 62
Children's Oncology Group 31
[disabled in preview] 114
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Paraplatin
Sponsor Trials
Other 611
Industry 300
NIH 291
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKinsey
Harvard Business School
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.